Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Inclusion Criteria:

• Diagnosis of gynecologic malignancy

• No chemotherapy in the last 12 months

• Scheduled to receive Carboplatin (AUC>=4) and Paclitaxel every three weeks

• ECOG performance status 0 or 1

• English speaking

• Willing and able to provide informed consent

• Laboratory values within protocol-defined parameters

• No vomiting in the 24 hours prior to initiating chemotherapy

• If childbearing potential exists, negative pregnancy test within 7 days prior toregistration

Exclusion Criteria:

• Significant cognitive compromise

• History of CNS disease (e.g. brain metastases, seizure disorder, dementia)

• Current or recent (within 30 days) treatment with another antipsychotic agent (antidepressant medications are OK)

• Concurrent radiotherapy treatment

• Known hypersensitivity to olanzapine

• Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardialinfarction within the last six months

• History of diabetes mellitus on medication (insulin or oral glycemic agent)

• Alcohol abuse / chronic alcoholism

• History of closed angle glaucoma

• Current enrollment in other clinical trials